Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata
Abstract
Background: The mechanisms driving alopecia areata (AA) are still unclear, hindering development of targeted therapeutics. Specific Th2 targeting with dupilumab in AA provides a unique opportunity to dissect its pathogenesis and explore the role of Th2 pathway.Methods: We evaluated changes in scalp biomarkers in AA patients (with and without concomitant atopy) randomized to weekly dupilumab or placebo for 24 weeks, followed by open‐label dupilumab for 24 weeks. Changes in biomarker levels were measured at weeks 12, 24, and 48 and were also correlated with clinical hair regrowth.Results: At week 24, preceding clinical hair regrowth outcomes, only dupilumab‐treated patients presented significant suppression of cellular infiltrates, and multiple Th2‐related, markers (CCL13/MCP‐4, CCL18/PARC, CCL26/eotaxin‐3, CCL24/Eotaxin‐2), coupled with significant upregulation in the hair keratins. Th1‐related suppression was evident later (week 48) when all patients received open‐label dupilumab. Results were more pronounced in atopic AA patients, that showed 48% and 97% improvements in the lesional AA scalp profile at weeks 24 and 48, respectively, while 2% worsening was seen in the placebo arm at week 24. Moreover, placebo‐treated patients presented 54% worsening in hair keratins when compared with baseline at week 24. At week 24, increases in hair keratins showed significant correlations only with decreases in Th2‐related markers.Conclusions: Scalp biomarkers provide evidence of dupilumab efficacy in AA, detected even prior to clinical response, with exclusive correlations between early suppression of Th2 markers and increased hair keratins. These findings strengthen previous reports suggesting a possible role for Th2 cytokines as AA drivers.Keywords
Funding Information
- National Center for Advancing Translational Sciences
- Regeneron Pharmaceuticals
This publication has 49 references indexed in Scilit:
- Single nucleotide polymorphisms in the promoter regions of Foxp3 and ICOSLG genes are associated with Alopecia AreataClinical and Experimental Medicine, 2012
- STAR: ultrafast universal RNA-seq alignerBioinformatics, 2012
- Follow-Up Study of the First Genome-Wide Association Scan in Alopecia Areata: IL13 and KIAA0350 as Susceptibility Loci Supported with Genome-Wide SignificanceJournal of Investigative Dermatology, 2012
- Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic responseJournal of Allergy and Clinical Immunology, 2011
- Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalitiesJournal of Allergy and Clinical Immunology, 2011
- Serum Interleukin‐4 and Total Immunoglobulin E in Nonatopic Alopecia Areata Patients and HLA‐DRB1 TypingDermatology Research and Practice, 2010
- History of atopy or autoimmunity increases risk of alopecia areataJournal of the American Academy of Dermatology, 2009
- Loss-of-Function Mutations in the Filaggrin Gene and Alopecia Areata: Strong Risk Factor for a Severe Course of Disease in Patients Comorbid for Atopic DiseaseJournal of Investigative Dermatology, 2007
- Interferon-γ-deficient mice are resistant to the development of alopecia areataBritish Journal of Dermatology, 2006
- Alopecia Areata Induced in C3H/HeJ Mice by Interferon-Gamma: Evidence for Loss of Immune PrivilegeJournal of Investigative Dermatology, 2005